First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study

This phase II study assessed the safety and efficacy of oxaliplatin and capecitabine in patients with advanced oesophageal cancer. Fifty-one eligible patients received oxaliplatin 130 mg m(−2) intravenously on day 1 and capecitabine 1000 mg m(−2) orally twice daily on days 1 to 14 in a 21-day treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: van Meerten, E, Eskens, F A L M, van Gameren, E C, Doorn, L, van der Gaast, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360191/
https://www.ncbi.nlm.nih.gov/pubmed/17437008
http://dx.doi.org/10.1038/sj.bjc.6603750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360191/
https://www.ncbi.nlm.nih.gov/pubmed/17437008
http://dx.doi.org/10.1038/sj.bjc.6603750

Ejemplares similares